| Brown, David W |
NCT04072354 / 2019-000470-36: A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia |
|
|
| Completed | 3 | 463 | Europe, US, RoW | SEP-363856 50mg, SEP-363856 75mg, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 05/23 | 09/23 | | |
NCT05779241: Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 |
|
|
| Completed | 3 | 83 | US | LYN-005, Risperidone, Risperdal | Lyndra Inc. | Schizophrenia, Schizoaffective Disorder | 11/23 | 12/23 | | |
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults with Soft Tissue Sarcomas |
|
|
| Recruiting | 3 | 333 | Europe, Canada, US | INT230-6, Eribulin, Trabectedin, Pazopanib | Intensity Therapeutics, Inc., Premier Research Group plc | Sarcoma,Soft Tissue | 12/27 | 12/28 | | |
ARCHER II, NCT06510816: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) |
|
|
| Recruiting | 3 | 630 | Canada, US, RoW | ANX007, Sham Administration | Annexon, Inc. | Geographic Atrophy | 10/26 | 10/27 | | |
| Completed | 3 | 410 | Europe, US, RoW | HLX04-O, ranibizumab | Shanghai Henlius Biotech | Age Related Macular Degeneration | 12/24 | 12/24 | | |
NCT04109950 / 2019-000696-16: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia |
|
|
| Terminated | 3 | 463 | Europe, US, RoW | SEP-363856 | Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc. | Schizophrenia | 11/23 | 11/23 | | |
| Completed | 3 | 97 | Europe, Canada, US, RoW | Genetic: AAV5-hRKp.RPGR, botaretigene sparoparvovec | Janssen Research & Development, LLC, Janssen Research & Development, LLC | X-Linked Retinitis Pigmentosa | 09/24 | 09/24 | | |
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. |
|
|
| Terminated | 3 | 83 | Europe, Canada, Japan, US | SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo | Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc. | Depressive Episodes, Bipolar I Depression | 10/23 | 10/23 | | |
| Active, not recruiting | 3 | 97 | Europe, Canada, US, RoW | Genetic: AAV5-hRKp.RPGR Intermediate Dose, botaretigene sparoparvovec, Genetic: AAV5-hRKp.RPGR Low Dose | Janssen Research & Development, LLC, Janssen Research & Development, LLC | X-Linked Retinitis Pigmentosa | 09/29 | 12/29 | | |
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia |
|
|
| Active, not recruiting | 2 | 350 | US | LB-102 | LB Pharmaceuticals Inc. | Schizophrenia | 12/24 | 05/25 | | |
GION, NCT06178055: A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) |
|
|
| Active, not recruiting | 2 | 75 | US | KUS121 high dose, KUS121 low dose, Sham procedure | Kyoto Drug Discovery and Development Co., Ltd. | Central Retinal Artery Occlusion | 03/25 | 12/25 | | |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
| Active, not recruiting | 2 | 179 | US | Faricimab | Greater Houston Retina Research, Genentech, Inc. | Non-Proliferative Diabetic Retinopathy | 03/26 | 04/26 | | |
NCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 146 | Europe, US, RoW | Iptacopan (LNP023), Placebo | Novartis Pharmaceuticals | Age-Related Macular Degeneration | 10/26 | 10/26 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
NCT05345769: Safety and Efficacy of AM712 in Patients with NAMD |
|
|
| Completed | 1 | 21 | US | AM712(ASKG712) | AffaMed Therapeutics Limited | Neovascular Age-related Macular Degeneration | 11/24 | 11/24 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
